Zobrazeno 1 - 10
of 23
pro vyhledávání: '"James M. Felser"'
Autor:
Jorge Maspero, Ioana Octavia Agache, Tadashi Kamei, Makoto Yoshida, Bryan Boone, James M. Felser, Fernando Kawakami, Barbara Knorr, David Lawrence, Thomas Lehmann, Wei Wang, Andrew J. Pedinoff
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-11 (2021)
Abstract Background The prostaglandin D2 (PGD2) receptor 2 (DP2 receptor) pathway is an important regulator of the inflammatory cascade in asthma, which can be stimulated by allergic or non-allergic triggers. Fevipiprant is an oral, non-steroidal, hi
Externí odkaz:
https://doaj.org/article/102c338f6f484e79ad4512e0f78c4a9e
Autor:
Nazzareno Galiè, Hyuk Jae Chang, Hans Klose, Wei Yang, Deborah A. Quinn, Marius M. Hoeper, Andrew J. Peacock, Hiromi Matsubara, Robert P. Frantz, Victor F. Tapson, Yoshihiro Fukumoto, Carmine Dario Vizza, Robyn J. Barst, Michael Pfeifer, James M. Felser, Fernando Torres, Paul M. Hassoun, Adaani E. Frost, Hossein Ardeschir Ghofrani, Gérald Simonneau, Nicholas W. Morrell, David Lawrence
BACKGROUND: Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e04ef7dc162143472d3791133f1170bc
http://hdl.handle.net/11573/901480
http://hdl.handle.net/11573/901480
Autor:
James M. Felser, Charles Lynde, Roland Kaufmann, Lawrence F. Eichenfield, Linda Lindsley, Anne W. Lucky, Nathalie Barbier, Gail Todd, Richard G. Langley
Publikováno v:
International Journal of Dermatology. 44:70-75
Background Pimecrolimus cream 1%, a cell-selective inhibitor of inflammatory cytokines, has been shown to be effective in treating atopic dermatitis (AD). This report examines the effect of ethnic origin and baseline disease severity on treatment out
Autor:
L. Pineiro, Joseph DiCesare, Marilyn Campion, James M. Felser, Ruben A. Saez, Roger H. Herzig, Joseph W. Fay, Brenda W. Cooper, Geoffrey P. Herzig, Hillard M. Lazarus, Robert H. Collins, Don A. Stevens, Steven H. Bernstein
Publikováno v:
Blood. 84:2151-2157
Preclinical studies of recombinant human interleukin-3 (rhIL-3) and granulocyte-macrophage colony-stimulating factor (rhGM-CSF) have shown enhancement of multilineage hematopoiesis when administered sequentially. This study was designed to evaluate t
Autor:
James M. Felser
Publikováno v:
Annals of the New York Academy of Sciences. 730:235-242
Hematopoietic growth factors are being used to accelerate the recovery of myelopoiesis following high-dose chemotherapy in cancer patients. G-CSF and GM-CSF reduce the duration of neutropenia following chemotherapy. Rapid restoration of neutrophils h
Publikováno v:
Respiratory medicine. 105(4)
SummaryPurposeAs COPD patients commonly suffer cardio- and cerebrovascular (CCV) co-morbidities, our purpose was to establish the CCV safety profile of indacaterol, a novel, inhaled, long-acting β2-agonist for COPD.MethodsThe indacaterol clinical tr
Autor:
Nancy J. Marinos, James M. Felser, Peter Dickie, Abner Louis Notkins, Jonathan Silver, Michael Eckhaus, Joseph Bryant
Publikováno v:
Virology. 185:109-119
Transgenic mice were produced that bore copies of a defective HIV provirus. The transgenic offspring from three independently derived mouse lines manifested renal disease associated with proteinuria, a high mortality rate, and HIV-specific gene expre
Publikováno v:
The Journal of pediatrics. 124(1)
Fanconi anemia is a congenital syndrome characterized by multiple specific physical anomalies, progressive marrow failure, and a predisposition to acute leukemia. We studied the toxicity and efficacy of daily subcutaneous administration of recombinan
Autor:
Richard A. Kaslow, Alvaro Muñoz, James J. Goedert, John P. Phair, Ann M. Labriola, James M. Felser, Frederick Hecht, Roger Detels, Charles R. Rinaldo, Alfred J. Saah
Publikováno v:
New England Journal of Medicine. 322:1607-1608
Publikováno v:
Virology. 170:566-570
We describe a syncytia assay that utilizes a noninfectious plasmid (pEVd1443) derived from human immunodeficiency virus type I (HIV-I). This plasmid carries a large deletion of gag-pol sequences but expresses HIV-I envelope proteins and induces syncy